{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O46676",
      "entity_text" : "GRO-alpha",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P25025",
      "entity_text" : "CXCR2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Treatment of ovarian cancer cells with GRO-alpha and IL-8 neutralizing antibodies or ablation of CXCR2 by shRNA gene knockdown, CRISPR / Cas9 gene knockout, or CXCR2 inhibitor SB225002 treatment significantly attenuated TAK1 / NFkappaB signaling and decreased in vitro and in vivo oncogenic and metastatic potential, suggesting CXCR2 plays a key role in the GRO-alpha and IL-8-governed metastatic spreading of ovarian cancer cells in the intraperitoneal cavity.",
  "reading_complete" : "2020-08-03T16:21:39Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T16:18:54Z",
  "trigger" : "attenuated",
  "evidence" : [ "CXCR2 by shRNA gene knockdown, CRISPR/Cas9 gene knockout, or CXCR2 inhibitor SB225002 treatment significantly attenuated TAK1/NFkappaB signaling and decreased in vitro and in vivo oncogenic and metastatic potential, suggesting CXCR2 plays a key role in the GRO-alpha" ],
  "pmc_id" : "5835935",
  "score" : 0
}